BP329

General Information


DRACP ID  DRACP00948

Peptide Name   BP329

Sequence  CLBCREKAKKLFKKILKKL

Sequence Length  19

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Coupling peptide



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
22Rv1 Prostate carcinoma Carcinoma LC50=50 µM MTT assay Not available Patent
CL1 Prostate carcinoma Carcinoma LC50>100 µM MTT assay Not available Patent
CAPAN-1 Pancreatic ductal adenocarcinoma Carcinoma IC50=33.0 ± 1.0 µM MTT assay 48 h 1
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=35.2 ± 1.8 µM MTT assay 48 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  NIH 3T3: IC50=33.7 ± 1.9 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C101H182N28O20S2

Absent amino acids  DGHMNPQSTVWY

Common amino acids  K

Mass  249411

Pl  10.92

Basic residues  8

Acidic residues  1

Hydrophobic residues  7

Net charge  7

Boman Index  -2863

Hydrophobicity  -31.58

Aliphatic Index  107.89

Half Life 
  /

Extinction Coefficient cystines  125

Absorbance 280nm  6.94

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 24480922

Title  Identification of BP16 as a non-toxic cell-penetrating peptide with highly efficient drug delivery properties

Doi 10.1039/c3ob42422g

Year  2014

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.